Today: 27 January 2026
Subscribe
Browse Category

Healthcare Industry News 23 November 2025 - 4 December 2025

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

Updated: 4 December 2025 CSL Limited (ASX:CSL), the Australian biotech heavyweight, is trading around A$183 per share on 4 December 2025 after one of the most bruising years in its modern history. The company has delivered solid profit growth, announced thousands of job cuts, delayed a major spin‑off, launched a A$750 million buy‑back and opened a A$1 billion cell‑based vaccine…
4 December 2025
···
McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (NYSE: MCK) is ending 2025 as one of the standout performers in U.S. healthcare — but as of Wednesday, December 3, its stock is taking a breather. At the close, McKesson shares finished at $805.37, down 2.93% on the day and roughly 10% below their recent 52‑week high near $895, even after a powerful rally through most of…
4 December 2025
···
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

As of December 2, 2025, CVS Health Corporation (NYSE: CVS) finds itself in a classic “good news, bad headlines” moment: the stock has pulled back after a strong 2025 rally, the company agreed to a federal settlement over insulin-pen billing, and yet Wall Street’s forecasts still point to further upside. Below is a structured rundown of the latest price action,…
3 December 2025
····
HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare Stock Near Record Highs: December 2025 Earnings, Forecasts and Policy Risks Explained

HCA Healthcare, Inc. (NYSE:HCA) is ending 2025 on a powerful note. After a year of double‑digit earnings growth and upgraded guidance, HCA stock is trading just above $500 per share, close to its 52‑week high of $520 and implying a market capitalization around $117 billion. MarketBeat On November 25, the stock touched an all‑time high of $515.85, and as of…
3 December 2025
···
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026. Below is a…
2 December 2025
····
CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

Updated: 2 December 2025 CSL Limited’s share price has spent most of 2025 in the sin bin, but behind the drawdown sits a mix of solid earnings growth, a radical restructuring, a forthcoming spin‑off of its vaccines arm and fresh news today about a major new vaccine plant and an active on‑market buyback. Together, these developments are reshaping the investment…
2 December 2025
···
CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

Data and news current as of December 1, 2025. This article is for informational purposes only and is not financial advice. CVS Health Stock Today: A Big 2025 Comeback, Slightly Off the Highs CVS Health Corporation (NYSE: CVS) has staged one of 2025’s quiet comeback stories. On December 1, 2025, CVS shares closed at $79.10, down about 1.6% on the…
2 December 2025
····
Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation (NASDAQ: EXAS) has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below…
1 December 2025
····
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact Sciences, and a safety correction affecting millions of Libre 3 glucose sensors, all against the backdrop of solid earnings and…
26 November 2025
····
Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck & Co., Inc. (NYSE: MRK) is suddenly back in the market’s spotlight. On Monday, 24 November 2025, Merck’s share price surged to around $102, up roughly 4–4.5% on the day, after a bullish analyst upgrade collided with fresh regulatory and pipeline news around its flagship cancer drug Keytruda. TradingView At the same time, Merck released new hematology pipeline data…
24 November 2025
····
Monash IVF (ASX: MVF) Share Price Soars as Board Rejects 80¢ Takeover Bid and Macquarie Sees 54% Upside

Monash IVF (ASX: MVF) Share Price Soars as Board Rejects 80¢ Takeover Bid and Macquarie Sees 54% Upside

Sydney – 24 November 2025 Monash IVF Group Ltd (ASX: MVF) has surged back into the spotlight today after rejecting an 80¢-per-share takeover proposal from a private equity–backed consortium, sending the embattled fertility stock up around 40–41% to about 86¢ and putting it among the top performers on the ASX All Ordinaries Index. Reuters The dramatic move comes just days…
24 November 2025
····
CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health stock is heading into the new week near the top of its 2025 trading range after a year of sharp gains, a headline‑grabbing goodwill write‑down, and a wave of fresh institutional ownership filings released today, November 23, 2025. At the same time, CVS is tightening up its strategy in primary care, overhauling its pharmacy benefit management (PBM) model,…
23 November 2025
····
1 … 5 6 7 8 9 10

Stock Market Today

  • Soybeans Retreat from Early Gains as Export Data Shows Mixed Signals
    January 27, 2026, 1:25 AM EST. Soybean futures dropped 4 to 5 cents on Monday after initial overnight gains, with March contracts at $10.63 per bushel. The national average cash soybean price rose slightly to $9.93 1/4. Export inspections revealed shipments of 1.324 million metric tons last week, down 1.54% from the week before but up nearly 80% year-on-year. China remained the largest destination. Marketing year shipments have increased 37.5% year-on-year. However, recent export sales are 22% below last year, underperforming USDA projections. Speculative traders reduced net long positions by nearly 3,000 contracts, reflecting cautious sentiment. Brazil's harvest is progressing briskly with a crop estimate raised to 181 million metric tons. Soymeal futures fell $3.90 to $4.70, while soy oil futures inched higher, indicating mixed demand pressures across related commodities.
Go toTop